Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) insider Tobin Juvenal sold 6,578 shares of the business’s stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $36.42, for a total transaction of $239,570.76. Following the completion of the transaction, the insider owned 38,853 shares in the company, valued at $1,415,026.26. The trade was a 14.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Castle Biosciences Stock Down 3.5%
Shares of NASDAQ:CSTL opened at $37.16 on Friday. The company has a 50-day moving average price of $34.22 and a 200-day moving average price of $28.68. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 12 month low of $17.72 and a 12 month high of $44.28.
Castle Biosciences (NASDAQ:CSTL – Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.34. The company had revenue of $99.86 million for the quarter, compared to analysts’ expectations of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. Equities research analysts expect that Castle Biosciences, Inc. will post -1.29 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the company. Global Retirement Partners LLC purchased a new stake in shares of Castle Biosciences in the second quarter worth $26,000. NFSG Corp purchased a new position in shares of Castle Biosciences in the 3rd quarter worth about $36,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Castle Biosciences in the 3rd quarter worth about $55,000. Quantbot Technologies LP bought a new position in Castle Biosciences in the 2nd quarter worth about $62,000. Finally, State of Wyoming purchased a new stake in Castle Biosciences during the 2nd quarter valued at about $117,000. Institutional investors own 92.60% of the company’s stock.
Analyst Ratings Changes
A number of brokerages recently commented on CSTL. Wall Street Zen lowered Castle Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 24th. BTIG Research lifted their price target on shares of Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Castle Biosciences in a research report on Thursday. Mizuho started coverage on shares of Castle Biosciences in a report on Thursday. They issued an “outperform” rating and a $60.00 price objective for the company. Finally, Robert W. Baird set a $36.00 target price on shares of Castle Biosciences in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $44.25.
Get Our Latest Stock Report on CSTL
About Castle Biosciences
Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company focuses on conditions in which additional biological information can complement traditional pathology and clinical assessment.
Its portfolio includes DecisionDx-Melanoma, which helps evaluate the risk of metastatic recurrence in patients with cutaneous melanoma; DecisionDx-SCC, which assesses metastatic risk in cutaneous squamous cell carcinoma; and DecisionDx-UM, a test for determining metastatic risk in uveal melanoma.
Featured Stories
- Five stocks we like better than Castle Biosciences
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
